ClinicalTrials.gg
RecruitingNCT07722130Updated Sep 4, 2026

Epidural Spinal Cord Stimulation for Respiratory Recovery in Cervical SCI

An interventional study of Epidural spinal cord stimulation in Spinal Cord Injury Cervical and Respiratory Failure, sponsored by Zhongda Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Zhongda Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This multicenter, single-arm exploratory IIT evaluates epidural spinal cord electrical stimulation (ESCES) in 20 adults with C1-C5 SCI and respiratory failure. Participants receive ESCES plus standard care; electrodes are implanted at C3-C5 with daily individualized stimulation. Primary outcomes: Edi peak, change of Edi peak and frequency. Secondary: tidal volume, maximal inspiratory pressure, NVE, NME, diaphragm ultrasound, cough strength, 90-day ventilator-free days, ICU stay, and survival. This is the first systematic ESCES study for SCI-related respiratory failure, aiming to provide preliminary safety/efficacy data for future RCTs.

Read the detailed description

This is a multicenter, prospective, single-arm, exploratory investigator-initiated trial (IIT) conducted at Zhongda Hospital, Southeast University and the First Affiliated Hospital of Nanjing Medical University. The study aims to evaluate the safety and efficacy of epidural spinal cord electrical stimulation (ESCES) in patients with spinal cord injury (SCI) complicated by respiratory failure.

A total of 20 adult patients (aged 18-75 years) with C1-C5 level SCI for at least 2 weeks and respiratory failure requiring mechanical ventilation or presenting with hypoxemia/hypercapnia will be enrolled. Participants will receive standard conventional treatment plus ESCES. Electrodes will be surgically implanted at the C3-C5 epidural space, and stimulation will be delivered daily with individualized parameter titration based on patient tolerance.

The primary outcomes are Edi peak, change of Edi peak and frequency. Secondary outcomes include tidal volume, diaphragmatic ultrasound parameters, cough strength, 90-day ventilator-free days, ICU length of stay, and survival at 90 and 180 days.

The observation period is defined as the period from enrollment until 1 month after enrollment or until successful weaning from mechanical ventilation, ICU discharge, removal of the epidural stimulation electrode, withdrawal from the study, or death, whichever occurs first.

This study is the first systematic exploration of ESCES for respiratory function recovery in SCI patients with respiratory failure, and may provide a novel therapeutic strategy for this population. The trial is expected to run for approximately 30 months. Participation is voluntary, and participants may withdraw at any time without affecting their subsequent care.

02

Conditions studied

  • Spinal Cord Injury Cervical
  • Respiratory Failure

Keywords

  • respiratory failure
  • spinal cord injury
  • epidural spinal cord electrical stimulation
  • diaphragm electrical activity
03

In context

Respiratory Insufficiency

1,369 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.

This study's planned enrollment of 20 is below the median of 60 across 860 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

Zhongda Hospital is the lead sponsor of 104 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years, with \<30 kg/m².
  2. Cervical SCI involving levels C1-C5 for at least 2 weeks.
  3. Respiratory failure defined by one or more of the following:

    • Peripheral oxygen saturation \<90% on room air;
    • Arterial oxygen tension (PaO₂) \<60 mmHg;
    • Respiratory acidosis (PaCO₂ >45 mmHg with pH \<7.35);
    • Requirement for mechanical ventilation.
  4. Maximum inspiratory pressure (MIP) >-15 cmH₂O.
  5. Judged by the treating physician to be unable to tolerate continuous ventilator weaning for ≥48 hours due to SCI.
  6. Written provided by the participant or legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Active infection at the planned electrode implantation site, severe systemic infection, or existing implanted neurostimulation devices.
  2. Respiratory failure primarily caused by severe pneumonia, pulmonary contusion, pneumothorax, hemothorax, , or requirement for home oxygen therapy within the previous 6 months.
  3. (NYHA) class III or IV heart failure or implanted cardiac pacemaker.
  4. Severe hepatic or renal dysfunction ( class C liver disease or estimated ≤30 mL/min/1.73 m²) or dialysis dependence.
  5. Generalized seizures, traumatic brain injury, intracranial hypertension, intracranial aneurysm with Glasgow Coma Scale score ≤12, or neuromuscular disorders affecting respiratory function.
  6. Expected survival \<72 hours or refusal of life-sustaining treatment.
  7. Pregnancy or breastfeeding.
  8. Any other condition considered by the investigator to make study participation inappropriate.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Epidural spinal cord stimulation

    Other: Epidural spinal cord stimulation

Interventions

  • OtherEpidural spinal cord stimulation

    ①Epidural electrode implantation Under general anesthesia, two epidural electrodes will be implanted through a posterior cervical approach and positioned over the dorsal epidural space at the C3-C5 spinal levels. An implantable pulse generator will be placed in the lateral chest wall. ②.Epidural Spinal Cord Stimulation ESCS will begin on postoperative day 2. Initial stimulation parameters will include: * Pulse width: 200 μs (maximum 500μs) * Frequency: initially 10 Hz, gradually increased up to 60 Hz (maximum 300 Hz) according to tolerance * Current intensity: initially 1 mA, increased in 0.5 mA increments to the maximum tolerated intensity (up to 20 mA) Stimulation will be delivered daily. Stimulation parameters will be recorded throughout the study, and settings may be adjusted to minimize discomfort. Additional supportive care will be provided as clinically indicated.

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Incidence of Adverse Events and Serious Adverse Events Related to Epidural Spinal Cord Stimulation; Safety will be assessed by the occurrence of adverse events (AEs) and serious adverse events (SAEs) considered possibly, probably, or definitely related to epidural electrode implantation, the stimulation device, or epidural spinal cord stimulation.

    Time frame: From epidural electrode implantation through Day 30.

  2. Diaphragmatic function

    Peak electrical activity of the diaphragm (Edi peak): Peak electrical activity of the diaphragm measured using an electrical activity of the diaphragm (Edi) catheter. Values are reported in microvolts (μV). Diaphragmatic electrical activity frequency (Edi frequency): Diaphragmatic electrical activity frequency measured using an electrical activity of the diaphragm (Edi) catheter. Values are reported as breaths per minute (breaths/min).

    Time frame: From epidural electrode implantation through Day 30.

Secondary outcomes

  1. Maximum tidal volume

    Maximum tidal volume measured by the mechanical ventilator during pressure support ventilation. Values are reported in milliliters (mL).

    Time frame: up to 1 month

  2. Change in peak electrical activity of the diaphragm (Edi peak) from baseline

    Change in peak electrical activity of the diaphragm (Edi peak) from baseline, Change from baseline in peak electrical activity of the diaphragm measured using an Edi catheter. Values are reported in microvolts (μV).

    Time frame: up to 1 month

  3. Frequency of spontaneous breaths triggered by diaphragmatic electrical activity

    The frequency of spontaneous breaths triggered by the patient's diaphragmatic electrical activity and detected using an Edi catheter. Breaths triggered solely by the mechanical ventilator without a corresponding Edi signal are excluded. Values are reported as breaths per minute (breaths/min).

    Time frame: up to 1 month

  4. Neuroventilatory efficiency (NVE)

    Neuroventilatory efficiency of the diaphragm, calculated as the ratio of tidal volume to peak electrical activity of the diaphragm (VT/Edi). NVE reflects the tidal volume generated per unit of neural respiratory drive and represents the integrated performance of diaphragm function and respiratory load. Values are reported in mL/μV.

    Time frame: up to 1 month

  5. Neuro-mechanical efficiency (NME)

    Neuro-mechanical efficiency of the diaphragm, calculated as the ratio of the change in airway pressure during an end-inspiratory occlusion maneuver to the corresponding peak electrical activity of the diaphragm (ΔPaw/Edi). NME reflects the pressure-generating capacity (contractile efficiency) of the diaphragm per unit of neural respiratory drive. Values are reported in cmH₂O/μV.

    Time frame: up to 1 month

  6. Airway occlusion pressure at 100 milliseconds (P0.1)

    Airway occlusion pressure measured 100 milliseconds after the onset of inspiratory effort using the ventilator monitoring system. Values are reported in cmH₂O.

    Time frame: up to 1 month

  7. Airway occlusion pressure during end-expiratory occlusion (Pocc)

    Airway occlusion pressure measured during an end-expiratory occlusion maneuver using the ventilator monitoring system. Values are reported in cmH₂O.

    Time frame: up to 1 month

  8. Maximum inspiratory pressure (MIP)

    Maximum inspiratory pressure (MIP) measured using an inspiratory pressure measurement maneuver. MIP represents the maximum negative airway pressure generated during a maximal inspiratory effort against an occluded airway and reflects global inspiratory muscle strength. Values are reported in cmH₂O.

    Time frame: up to 1 month

  9. Diaphragm thickness

    Diaphragm thickness measured by diaphragm ultrasonography. Values are reported in millimeters (mm).

    Time frame: up to 1 month

  10. Diaphragm thickening fraction

    Diaphragm thickening fraction measured by diaphragm ultrasonography. Values are reported as percentages (%).

    Time frame: up to 1 month

  11. Diaphragmatic excursion

    Diaphragmatic excursion measured by diaphragm ultrasonography. Values are reported in millimeters (mm).

    Time frame: up to 1 month

  12. Acute Physiology and Chronic Health Evaluation II (APACHE II) score

    Disease severity assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. Scores range from 0 to 71, with higher scores indicating greater disease severity and a higher risk of mortality.

    Time frame: up to 1 month

  13. Sequential Organ Failure Assessment (SOFA) score

    Organ dysfunction assessed using the Sequential Organ Failure Assessment (SOFA) score. Scores range from 0 to 24, with higher scores indicating more severe organ dysfunction and worse clinical status.

    Time frame: up to 1 month

  14. Daily time off mechanical ventilation (hours/day)

    Total duration per day during which the patient breathes spontaneously without mechanical ventilatory support. Values are reported in hours per day (hours/day).

    Time frame: up to 1 month

  15. Ventilator-free days within 90 days

    Number of days alive and free from invasive mechanical ventilation during the first 90 days after enrollment.

    Time frame: Within 90 days after enrollment.

  16. Intensive care unit (ICU) length of stay

    Length of stay in the intensive care unit, reported in days.

    Time frame: up to 90 days

  17. Hospital length of stay

    Total length of hospitalization, reported in days.

    Time frame: up to 90 days

07

Study locations

2 of 2 sites recruiting
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210009, China
    Recruiting
    • Wenbo Fei Li, MD. PhD. · Contactliwenb1@126.com · 15250963911
    • Wenbo Li, Dr.PhD. · Sub investigator
    • Jin Fan, Dr.PhD. · Principal investigator
  • Zhongda Hospital, Southeast University
    Nanjing, Jiangsu 210009, China
    Recruiting
    • Fei Peng, Dr. PhD. · Contactafei0312@163.com · 15950565786
    • Jianfeng Xie, Dr. PhD. · Contactjianfengxie01@seu.edu.cn
    • Fei Peng, Dr.PhD. · Sub investigator
    • Jianfeng Xie, Dr.PhD. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 359 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 30 months is above that.

Counting every sponsor, half of 375 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 23, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Mar 31, 2029
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07722130
Lead sponsor
Zhongda Hospital
Collaborators
The First Affiliated Hospital with Nanjing Medical University, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences
Responsible party
Fei Peng (Sub-Investigator, Zhongda Hospital) — Principal investigator
First posted
Jul 23, 2026
Start date
Jun 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Sep 4, 2026

Study contacts

Fei Peng, Dr. PhD.
Contact
afei0312@163.com
15950565786
Jianfeng Xie, Dr. PhD.
Contact
jianfengxie01@seu.edu.cn

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion